Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non‐gemfibrozil fibrate trials is a research paper published in Journal of Internal Medicine (2024). On theSindex it has a DataRank of 0.208. It has been cited 3 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Region Hovedstaden
Grant: A7165
Region Hovedstaden
Grant: A7272
Japan Society for Science Promotion Postdoctral Fellowship for Research Abroad
Grant: 202360405
FWCI
0.98
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords